CD31 is the non-substrate ligand for CD38 (ref. 33): CD38/CD31 interactions activate signaling pathways modulating growth and motility of CLL cells. 17 CD31 may be expressed by CLL cells and it is ...

Ligation of CD38 with the agonistic IB4 mAb is known to start a signaling pathway in distinct cell lineages and derived models, 10 including CLL. 28 ERK1/2 is a molecular target shared by the ...

Multiple myeloma cells uniformly overexpress CD38. We studied daratumumab, a CD38-targeting, human IgG1κ monoclonal antibody, in a phase 1–2 trial involving patients with relapsed myeloma or ...

Currently, there are three CD38/CD3-targeting BiTEs to treat MM – all of which are in phase I clinical trials. It was recently shown that an anti-CD38 bispecific antibody, AMG424, was able to ...

Daratumumab is a human IgG1κ monoclonal antibody directed against CD38, which is expressed at high levels on plasma cells. The mechanisms of action of daratumumab include complement-dependent ...

Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Quiver AI Summary Y-mAbs Therapeutics, Inc. announced the ...

(C) Identification of populations in the naïve B cell gate (IgD + CD38 low). (D) Identification of populations within the memory-like gate (IgD - CD38 low) and the pre-GC gate (IgD + CD38 +).

CD38 is an enzyme with NAD-depleting and intracellular signaling activity expressed on the cell surface, in intracellular compartments and in mitochondria, and is linked to inflammatory and autoimmune ...

Among 84 patients evenly split in each arm, HexaBody-CD38 elicited an ORR of 55% compared to 52% in the daratumumab arm. The complete response rate was 7% for HexaBody-CD38 and 2% for daratumumab.

Following a thorough evaluation, and rigorous portfolio prioritization, Genmab will not be pursuing further clinical development of HexaBody-CD38. Genmab said that it is "disappointed that J&J has ...

Primary Source Chen Y, et al "A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia" N Engl J Med 2024; DOI: 10.1056/NEJMoa2400409 Secondary Source Additional Source Comment ...